---
title: "Celcuity plunges 16% as breast cancer drug launch delayed to Q3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292802879.md"
description: "Celcuity (CELC) tumbles 16% in regular trading after delaying its approved breast cancer therapy launch to Q3."
datetime: "2026-07-15T18:01:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292802879.md)
  - [en](https://longbridge.com/en/news/292802879.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292802879.md)
generator: "portal-rs"
---

# Celcuity plunges 16% as breast cancer drug launch delayed to Q3

Celcuity(CELC.US) 盘中跌**16.2%**，现报**93.06 美元**。

公司宣布将推迟发布其最近获批的乳腺癌治疗药物至第三季度，此举导致股价出现双位数跌幅。

尽管面临此挫折，华尔街分析师仍维持积极评价。Stifel Nicolaus 维持买入评级，目标价**175 美元**；H.C. Wainwright 亦维持买入评级，目标价**155 美元**。

### Related Stocks

- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

- [Celcuity submits FDA sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer](https://longbridge.com/en/news/297045627.md)
- [Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports Valuation](https://longbridge.com/en/news/296708642.md)
- [Celcuity Analysts Slash Their Forecasts After Q2 Loss](https://longbridge.com/en/news/295935858.md)
- [Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295849905.md)
- [CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/294642754.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**